S

ST Pharm Co Ltd
KOSDAQ:237690

Watchlist Manager
ST Pharm Co Ltd
KOSDAQ:237690
Watchlist
Price: 146 700 KRW -2.72% Market Closed
Market Cap: ₩3T

Gross Margin

40.1%
Current
Improving
by 3%
vs 3-y average of 37.1%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
40.1%
=
Gross Profit
₩127.7B
/
Revenue
₩318.3B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
40.1%
=
Gross Profit
₩127.7B
/
Revenue
₩318.3B

Peer Comparison

Country Company Market Cap Gross
Margin
KR
ST Pharm Co Ltd
KOSDAQ:237690
3T KRW
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.1T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
204.9B USD
Loading...
US
Danaher Corp
NYSE:DHR
153.2B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
46.3T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
35.4B CHF
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
280B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
36.9B USD
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
32B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
28.3B USD
Loading...
US
Waters Corp
NYSE:WAT
22.8B USD
Loading...

Market Distribution

Higher than 78% of companies in Korea
Percentile
78th
Based on 2 511 companies
78th percentile
40.1%
Low
-646.5% — 12.8%
Typical Range
12.8% — 32.2%
High
32.2% — 54 001.3%
Distribution Statistics
Korea
Min -646.5%
30th Percentile 12.8%
Median 19.7%
70th Percentile 32.2%
Max 54 001.3%

ST Pharm Co Ltd
Glance View

Nestled in the bustling metropolis of Seoul, South Korea, ST Pharm Co Ltd. operates as a dynamic player within the global pharmaceutical industry. Established initially to meet the burgeoning demands of the local pharmaceutical market, the company has slowly carved out a niche for itself in the global arena. With a deft focus on the development and manufacture of active pharmaceutical ingredients (APIs), ST Pharm now sets its sights on becoming a central figure in the synthesis of high-value APIs used in therapies including antivirals and oncology treatments. This focus isn't merely driven by opportunity; it's underpinned by a dedicated commitment to cutting-edge research and development. The company has invested heavily in state-of-the-art facilities and nurtures a team of seasoned scientists who remain at the forefront of innovation. ST Pharm makes its revenue by mastering the art of efficient and reliable API production. By optimizing their production processes, they can offer a competitive edge—delivering high-quality products at scale. The company isn't solely interested in the immediate gains of API manufacture; it also sees potential in providing customized solutions to its diverse clientele, which spans multinational pharmaceutical giants to nimble biotech startups. Partnerships and collaborations have become crucial strategies for ST Pharm, facilitating an exchange of innovation and expertise that keeps them relevant and forward-thinking. In this regard, their business model elegantly balances between standardized API production and bespoke chemical solutions, ensuring a steady revenue stream while opening doors to future advancements in pharmaceutical science.

Intrinsic Value
85 883.1 KRW
Overvaluation 41%
Intrinsic Value
Price
S
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
40.1%
=
Gross Profit
₩127.7B
/
Revenue
₩318.3B
What is ST Pharm Co Ltd's current Gross Margin?

The current Gross Margin for ST Pharm Co Ltd is 40.1%, which is above its 3-year median of 37.1%.

How has Gross Margin changed over time?

Over the last 3 years, ST Pharm Co Ltd’s Gross Margin has increased from 36.3% to 40.1%. During this period, it reached a low of 34.9% on Sep 30, 2024 and a high of 40.1% on Oct 30, 2025.

Back to Top